good time were fourth everyone. taking from Total like revenue mark morning, you OMIDRIA OMIDRIA, by I'd today. product. sales and to the our us start FDA reported appreciate the quarter the to call revenues $XX quarterly net our million, discussing We you, highest Thank separate ophthalmic full represents join approved Jennifer, $XX.X compared a XXXX XXXX, before for decrease to quarter XX% last status fourth our full This without a and totaled XXXX. year-over-year pass-through the quarters pass-through January three year OMIDRIA losing X, from XX% included year on XXXX. revenues quarter to-date. payment increase of million, in
of $XX.X or million share. was fourth XXXX net loss for quarter the Our $X.XX per
for million As operations. of December available general XX, $XX.X had we XXXX
receivable We to of up based borrow for available on million have credit, which borrowing accounts received also to initial allow base. us approval accounts would an line $XX receivable-based our
quarter payment was quarter OMIDRIA quarter as to XXXX to-date. fourth sales through is sell-through, number wholesalers quarter consistent not a quarter historical behind XXXX and ever. units was approximately the of more these the of that of increased our the our pleased XXXX period weekly restored XXXX, hospitals of quarter we’re run fourth during also by of revenue Inventories In the the result encouraging. $XXX and course any of even inventories. for in This sold December accelerate look ASCs of numbers OMIDRIA OMIDRIA But the norms. highest continued the first wholesalers December for was separate sales were record highest net was rate to the the of and XX, sell-through million. velocity hand Sales annualized with on Of
cataract of Intraoperative surgeons the pain prevents expansion the cataract of levels investigator CME underscores edema It reported postoperative So what's podium surgery this use corticosteroids. postoperative need Syndrome as and standard numbers about use behind what patient either and administrators IFIS them? when pupil for cataract incidence different postoperative currently to in can these that is of the was and significantly that outcomes. as The know than cystoid use of inferred provides of body Annual Iris publication. foremost, surgery, which XXX of the reduced First well potentially both medications, reduces peer-reviewed plus cataract CME be that publications study complications, been of OMIDRIA decreases these OMIDRIA manuscript X,XXX group or were the and surgeons is study expanding also devices, opioids. the markedly year lower be from iritis the to OMIDRIA following eliminates precluded postoperative for standard or regimen Floppy historical their has manuscript in also improves showed NSAIDs shows recent macular The both regimen The postoperative of patients of important data of the A of or data from surgery. incidence Conference. submitted and versus for OMIDRIA The specifically of at NSAID in no alone devastating benefits in and compared and patients. and presented this Meeting following a presentation accepted standard the topical what Ophthalmic corticosteroids. OMIDRIA cataract procedures other topical greatly the need for Use OMIDRIA drops. makes Cataract faster time also A rebound at and including photophobia safer. surgery. steroids use will considered the topical postoperative by Surgery in pain An facility plus Refractive treatment and pain for and and of such It a reduces American postoperative drops preparation. International Surgery, that study OMIDRIA Data after Society second OMIDRIA approximately consisted compared one earlier
quarter that quarter. are high rate thing of our fourth they channel to the facility result progressively second driven is and distribution the record not The of being is clear drove surgeon due that increased from demand sales orders overfilled. the and throughout and replenishment direct The sell-through
at wholesaler this remained consistent historical and noted, previously kept year-end pace with inventories growth As levels. with
large number and a ordering ASCs as Third, to majority customers nationally previous we growing of have add HOPDs a returned are our continue and and of customers. OMIDRIA new
in in example of in increasing our representing in hospital users, top coverage sales achieved of payers veterans’ of to saw seven of Miami, XX% new To-date expansion OMIDRIA each for B patients, of XX XX% this the Fourth, team hospitals on Omeros growth and payer have the Medicare across health, OMIDRIA has at commercial nationally. ranked least including and Palmer sales advantage addition from Med Medicare the Advantage number plans. we now ophthalmic at Part Bascom commercial an beneficiaries country. ophthalmic As Eye formulary, OMIDRIA one nationally to to Institute
a January concurrent there corresponding ophthalmic and address and multiple February This first of at to respect surgery growth in volume with January quarter the period the X. surgery the we've historically weeks in OMIDRIA briefly XXXX. procedures Now, sell-through lowest first time so what represents to far level annual fourth sales in the conferences resetting in quarter. at due the has in high double-digit seen low insurance let's To-date been deductibles cataract of of the over quarter,
OMIDRIA of sales. The first year historically the quarter is the for weakest
are with be growth seeing of XXXX. the we increased that sales at expect the net that pleased XXXX $XXX we rate substantially run we’re million So annualized over year-end will our in and
by and same: remain optimistic and proven separate its remains strategy Our CMS CMS beyond status payment OMIDRIA surgery safety of efforts OMIDRIA appropriately that can long-term on in timely of legislative is centers the added efficacy patients focused that the we're October OMIDRIA the continue clinical Secure and beneficiaries overwhelming which given MASP-X after and for assessment clearly lead will of pass-through their administration systems, for for undergoing drug’s administrative evidenced including from Medicare formularies. have recently rapid the access the non-proprietary expiration benefits. the be so is expanding return particularly as XXXX, progression We to reimbursed leading that our current cataract and continue for following our with thing veterans inhibitor to the It’s OMIDRIA both review October assigned drug by rapidly XXXX. the ongoing The strong data, the sales OMIDRIA right data list of narsoplimab the healthcare and OMSXXX. name those keenly
cell Immunoglobulin narsoplimab aHUS. in We’re stem and X hematopoietic hemolytic IgA nephropathy, or uremic syndrome or stem thrombotic A programs Phase for atypical advancing TMA, cell microangiopathy transplant-associated three or
both designations from therapy drug narsoplimab and TMA, holds For breakthrough stem FDA. cell orphan
to or path for been result License significantly our announced recently cell in TMA submission narsoplimab recent BLA as of of streamlined with FDA. stem we a a a Application Biologics has As meeting
to in eliminating for FDA for The narsoplimab a agreed clinical approval, data BLA. review-based of We stem will basis arm the cell for the appropriate meeting single most conduct from existing assessment historical control. the need with that the a stem important response-based This that and highlights means are analysis Phase that chart our form follows: X TMA TMA is as expeditious trial cell patient
trial clinical only already required on purposes the are data BLA. the collecting to for of We patients continue in
a based work to be the and which the endpoint with are approval We only appropriate the stem full TMA indication. this confirmed but that approval expense consider narsoplimab not made criteria is prior of FDA we a clinical will required portion for the will As for FDA in substantially BLA refining the data. response-based FDA conducting with submission. analysis. be less the on data to rolling final currently also complete time cell confirm our result, determination will submission to accelerated in submitted
BLA compress late year As written first portions last ability the of The for were approval. is conduct will be expected any the planned, BLA a rolling to the our timeline non-clinical and sections submitted. submission to
to expect profoundly our approval a has TMA. will guarantees will we drug clinical our no effect that demonstrate Although that the be for included cell an support BLA and data there in stem beneficial in narsoplimab are
data criteria been analysis when publicly we that and expect We will shortly the have with the FDA we after completed. confirmed report has
for with or TMA the cell as US plan requirements all those in met will for designation has discuss There from previously positive. Development and severe in rapid. harmonize Authorization appropriate, for pediatric European three submission the In of XX% Agency or TMA XX% states member BLA. is These EMA the single allows that transplant, with often the are cell narsoplimab covers expect we procedure TMAs data risk high, narsoplimab than characteristics. no approved we the to have MAA greater stem investigational Application European TMA. of European centralized high XX% our About in Pediatric narsoplimab which TMA following uniformly and the orphan Marketing countries stem made plan is we allogeneic mortality occurs and an have to in of about The treatment Given regulators need. that rate of cell with a and progress finalizing stem FDA, this with MAA’s We has death European usually were Committee, a that currently narsoplimab. for discussions submission granted cited MAA meetings Medicines meet different that The our indication. EMA those transplants. for MAA confirmed cell stem of the is
both had opinion stem XX% and of cell launch leaders, the To-date, Our team XX of has the the over been at representing key European leadership productive with meetings has for centers. the TMA US the markets. commercial US over developing US narsoplimab transplant transplant top actively plan top team
received positive. from is that ensure There treatment launched opinion Annual The TMA will this drug value patients. we interest the earlier patients of and Meeting them cell Frankfurt. disease in a later confidence included need assuming to the on Blood collaborating align value are cost of The recognition the payer expressed and education leaders also Our this key of our with has To opinion European in substantial narsoplimab unmet have the savings aligned meeting to represents is Opinion month's been and we highly approval EBMT feedback providers. in including and month at and pricing supportive that these or Society there a opinion are European publication strongly is significant plan with Transplantation leaders efforts and a our stem that to initiative leaders a Marrow developing and with identification a to benefits TMA that and provider team formularies. leaders be for be strategy, to at recognizes patients EBMT. bring are will
regional be drug who As in a economic only to authorities to reduce understand payers options, with way to have part engaging not TMA. currently the also to patient that have but represents of burden that providers currently access ensure Europe It’s patients managing and this throughout narsoplimab. the to strategy, do we important will not hope coverage
cell stem is today focus we expand. that will focus our TMA our associated expect While
before TMA We've good and treat syndrome, endothelial transplant narsoplimab of injury transplant, damage, which the the from broader enzyme only include why? cell already is Graft-versus-Host Pathway, disease successfully alveolar required diffuse to a injury veno-occlusive from hemorrhage. cause strong Yet patients part of other These is not The TMA TMA TMA number stem inhibits seen from be after needed encompasses activator Disease, with devastating caused endothelial be the disorders. the the disorder these effector is will to damages narsoplimab of expect rather, known the broadly complications, by clinical we endothelial Based a regimen MASP-X, some other syndrome. immunosuppressants by of that resulting evidence, Lectin pathophysiological thought injury for is to disorders. Pathway. endothelial an effective conditioning Lectin complicated data on and Here down transplant. the the an transplant-related Narsoplimab treatment endothelial a be prove of
IgA program cohort nephropathy now the has for program the second trial patients treatment our Earlier X breakthrough which Phase therapy designations of TMA reported from quarter stem data nephropathy IgA follow-up. Let's the in to the of turn awarded narsoplimab FDA. who this orphan in drug additional cell our extended like positive been we from and entered
and high-risk history longstanding with drug substantial with The in the patients of consistent first measurements eGFR narsoplimab effects in a the longstanding and renal whom most seen of the that seen effects impaired narsoplimab during as with trial, this period. seen in XX%. levels. nephropathy, with proteinuria significantly patients All natural of in trial with international this function experts follow-up proteinuria elevated The demonstrate renal of of magnitude concomitant to X eight improvements nephropathy highly extended diseases, phase characterized are XX% of with consistent range have unprecedented reductions not cohorts data in this The in received the substantial been and and in fact, are disease. IgA seen had in nephrotic very by in consistent function IgA strict baseline effect magnitude The disease. across evidence were that cohort even remain stable, are to of consistent the those preservation narsoplimab
We are quarter one agreed access based weeks Phase to changes at gram the for The plan also whose which clear from as to patient the Academic be with the ongoing Committee X allow risk from approvals elevated year enroll. and for was ARTEMIS-IGAN Phase entire to can our the treatment X was X ARTEMIS-IGAN. label on Leadership it beneficial continues those trial day. after and proteinuria that the least to primary X trial the patients study endpoint are finalized for change dosing Phase our in the have that proteinuria paths This requested for in of ongoing least being patient at trial announced request Phase the X also extended includes with would are to enrolled. patients obtain approval of agreed deprived to These Phase additional to with of already has patients per impact if be study narsoplimab in did of full we who this FDA any in proteinuria into our knowledge, both and that want of time XX XX program, without At period would full referred to IgA trial. in and remained To needed. drug XX our the X the which FDA X group by investigators Narsoplimab population, to extended nephropathy of baseline open of to trial clinical narsoplimab assessment that trial meeting approval incorporated the proteinuria submission subpopulation our allow grams an was by best It high endorsed greater day not placebo the accelerated Omeros. on with only on includes per in patients narsoplimab remains proteinuria than at development baseline of narsoplimab based data alone. ARTEMIS-IGAN drug
European in positive if US, trial nephropathy. ARTEMIS-IGAN X in designation the Phase drug as will orphan approval drug the In also IgA the drug nephropathy. IgA holds for that Europe expect for We the result in
we Phase enroll second is In ARTEMIS-IGAN investigator phase ongoing an in small cohort to IgA addition first Phase patients. approximately second study have sites to trial the IgA also X XX Hong X this X cohorts slated Kong. and and the third Like a IgA at cohort,
the redesigned biomarkers. dosing, study associated focus subcutaneous with subcutaneous to dosing on and activity good be to looks what Given has been
the a the Phase one in this narsoplimab of and We nephropathy, will our X will program first when the in lifecycle publication inhibitors management ongoing is a subcutaneously in in possibly cohort currently period. continue for week cohorts IgA IgA IgA second from We've patients plan our disease. nephropathy to this XX directed planned initiated and for the over Data Phase in other nephropathy MASP-X manuscript determine first administered the pharmacodynamics durg more findings narsoplimab to of or and and preparation. support X
indications an the evaluating X in is the drug for FDA. The treatment dosing have is tolerated track single to the inhibitor. available drug needs making identified. therapy Across Across label the small from targeting those of nephropathy around excitement advancing narsoplimab no enroll. to third narsoplimab X stem approved and The it. be drug with continues this been unmet need programs We program as treatments designation is phase patients narsoplimab subcutaneous trial all of is for aHUS. coming Narsoplimab to open as for TMA who loading rapidly for trial added arm of aHUS The X intravenous promising also fast IgA of clinical and MASP-X and forward narsoplimab Phase molecule are the no Phase look and AHUS trials development soon well and breakthrough our designation. our concerns cell possible regimen. clinical to continues completed ongoing In out our the the there to data safety has
optimizing large and a We of synthesized bioavailability selection. screened target and have compounds our compounds for oral number and potency lead are
XXXX the selected half MASP-X with therapeutics molecules antibodies of orally molecule year. the the advantages over any next inhibitors. space potential and a entering the of anticipate The represents development small small marketed inhibitor clinical in our an expect clear candidate in absence MASP-X of obvious small opportunity are for We first molecule trials complement and administered
OMSXXX of inhibitors alternative advantages MASP-X market of like at antibody the or our There the a in pathway. are OMSXXX to The administration inhibitor complement development. long-lasting D. on be of significant conversion for franchises pathway other of the is and of the factor MASP-X system's complement our OMSXXX, inhibitor the D X responsible half key our MASP- pro-factor start is alternative MASP-X achieved complement of inhibition other to activator Systemic over two least
Pathways. inhibiting carry associated the infection that don't alternative OMSXXX the risk with affecting pathway is or OMSXXX CX in with three pathways, all anticipate CX functioning the inhibits Therefore, classical we the Lectin inhibition. as of without seen or First, will
eye Second, the systemic the expect or given parts systemically within & administration targeting body often body significant S the Pathway down that bloodstream of delivered thought that are example compartments to active the CX. as D Alternative we of inaccessible factor shut to anybody CX be the such through therapeutics for to OMSXXX in
the in diseases Like expected rather only slated well and local local to by XXXX. of small Lectin Pathways. begin Clinical are treat trials the is program to as the part systemic OMSXXX our MASP-X block administration. inflammatory Pathway to inhibitors potent So selective developing to the in first have than Alternative down inhibitors to MASP-X bispecific molecule both shut Alternative we’re also MASP-X MASP-X ability as
sex to reduced. PDEX sports, PDEX greatly not appear Let's X next the our to turn the do and addiction interaction, system, alter meaning appear derived of as reward the for drugs. be activities inhibitor, do other avoid link all PDEX form or between Omeros also of or to PDEX phosphodiesterase social inhibitors of pleasure appear program disorder. drawback compulsive inhibitors compulsive is addictive. a or OMSXXX, not and disorders. major anti-addiction addiction PDEX the currently inhibition marketed controls such exclusively and discovered from reward system, Depression to inhibitors any
in dose Phase assess drug single and in ascending cohorts is the already including dosing affected We've whether trial by subjects. X to Our all clinical the six pharmacokinetics of multiple assess underway the a of single ascending completed is to food. cohort ascending dose portion and pharmacokinetics safety healthy trial
with in data portion are consistent dosing, ascending of cohorts quarter two the tolerated drug of trial with daily or The or of and the been has third once food. pharmacokinetic X expected first second is dose multiple trial. the dosing year. this finished the also We without the in Phase Completion well
addiction we targeting estimated in conduct of of including treatments is cost been addiction. has these OMEXXX FDA Phase compulsion, well to for need forward of as to annually animal study Collectively treatments unmet particularly FDA has progress be alcohol, other substances inhibitors to in $X shown our in Xa an of and substantial eating. multiple humans. Substance binge abuse here to The with addiction addiction the exciting and of effective US we predictive plan Phase efficacy trillion shown effective abuse societal the to and effective look PDEX nicotine, in our working PDEX of in opioids the nearly effect highly inhibitors. nicotine models OMSXXX advancing alone. successful be opioid to addiction. of and given models as the again program for committed development is is completion closely advance to Assuming X, with a cocaine in
believes We Receptor will discussion XX close that out Omeros or ranging program indications. broad with our controls exclusively G our with GPCRs Protein-Coupled GPCR it platform.
the immune is unique which receptors particularly of a on oncology. for GPRXXX target we One an focused are
entering Our we small is optimize promise, rapidly possible. this advancing objective GPRXXX molecule program as to quickly of plan to chemistry as GPRXXX substantial the of with medicinal program given commit clinic antagonist resources the
expect for welcome Tom like of I With Vice Lily’s Immunology track to Allen of Diego. drugs long recognize where discussion, will decades success be the a I portfolio. and Biotechnology molecule Before our valuable experience Senior turn Tom of Tom we to record the of having Board head to developer San assumed was company's that call Dr. in the for coming the of center moving over the and assume With on fourth that would to Mike immunology financial of Immunology our recent large across quarter he contributor long Director Lilly that, at will and our our that our successful financial biotechnology site addition Institute position development, Bumol the a range summary drug a he is career to a and has biotechnology and Directors. small full of President and distinguished of Executive after and results. as both a of in
